Ok, sounds like a joke - but seriously, TuDiabetes is growing like gangbusters! Meredith Cummings wrote a great article on TuDiabetes and its explosive growth! The online community for people touched by diabetes, is growing at a rate of 10% per week. Way to go, Manny!

And why shouldn't we all plant a flag in this real estate? TuDiabetes offers nonstop support through conversations, debates, mysteries and revelations - all amounting to some degree of resolve. TuDiabetes is a great place to remind you that we're not alone in this dark tunnel. Need some light? Ask and you shall receive. And, by the way - you can get the answer to the lightbulb question by signing in and friending Meredith Cummings.

I logged in today and saw a great question. A member named Cody asks if others are annoyed when people who don't know what it's like to be diabetic try to offer advice. The group of interlopers is frankly growing like a virus. I define the interlopers as people who feel they know the world of diabetes without having landed on the tarmac! It's easy to study the playbook. It's a whole different ballgame to get your butt on the field. Good luck with college, Cody!

Creator of Diabetes Health Magazine, Scott King, has been a type 1 diabetic for over 34 years. Needless to say, he knows diabetes, and he is doing a remarkable job of introducing cutting-edge treatments for diabetics. In the first Diabetes Health TV broadcast, he shared interviews from the recent AADE Conference. A really exciting product he featured is called Neuragen - a topical treatment for diabetes neuropathy.

With diabetes neuropathy, people experience pain due to damage to the peripheral nerves. Neuropathic pain is often characterized by burning sensations or shooting pain, or may occur as numbness or chronic itching. Clinical trials have shown Neuragen to be effective in 70% of patients for the pain associated with diabetes. The ingredients are pretty kosher, too. Neuragen is made of a proprietary blend of essential oils from special species of geranium, lavender, bergamot, eucalyptus, and tea tree.

The Neuragen rep was blunt when he described the effective nature of this all natural product - using more does not make it any more effective! You have to admire his refreshing honesty. But like I said upfront - if Scott King is willing to spend the time getting the scoop on this product - it's probably worth your time using it. For more interviews, checkot the full coverage of the AADE Conference on Diabetes Health TV!

Jennifer Ordoñez, a Newsweek journalist who is also a Type 1 diabetic, reported on her experience at a triathlon training camp geared for diabetics. After reading her report, I was curious as to why hypoglycemia would cause a diabetic to fail the VO2 max test.

Nobody likes failing tests - especially when it comes to something as important as VO2 max. VO2 max is the maximum amount of oxygen a person uses while exercising at their limit for one minute. If you are in shape, your muscles will use a lot of oxygen to create energy. The prime source of energy for the body comes from blood sugar. When Jennifer took her VO2 test her blood sugar was falling and she failed. Apparently when blood sugar is falling the body puts itself into energy lockdown which compromises even conditioned athletes VO2 max.

Hypoglycemia causes muscles to fatigue quicker. Muscle fatigue is the result of inadequate oxygen availability. Prevention of hypoglycemia is one of the major objectives of adequate blood sugar when you are about to work out. By maintaining optimal blood sugar, you can assure a better level of exercise performance. I know better than to tell you what to do. But as a friendly reminder: make sure you've fueled up adequately before you hit the gym or the open road to work on your VO2 max.

Bev did a great job covering the study of obese mice having protection from elevated blood sugar due to a plethora of adiponectin. Adiponectin was shown to enhance insulin signaling which transported the excess glucose to less harmful areas of the body, rather than the cells which would endure diabetes complications. The results of this study created a condition called ratones mórbidamente obesos - which sounds better in Spanish because in English this means morbidly obese mice.

You know what they say about hindsight, right? A study from a year ago revealed some good news and some bad news. Good news first - turns out Type 2 diabetes drugs using troglitazone increased adiponectin. Rezulin was one of these drugs, but it was removed from the US market March 21, 2000. Now the bad news, the Type 2 diabetes drugs made with metformin were shown to reduce adiponectin. A few of the drugs that use metformin are Fortamet, Glucophage, Glucophage XR, and Riomet.

So why must diabetics be led with imperfect vision? Because the bottom line is researchers and doctors believe they are saving lives every day. Yes, they do. But there is a lot to behold when you tinker with His design. Remember the movie Malice? These lines don't make it into movies for nothing. Producers know human nature and they stretch it to the extreme. Whether or not you want to admit it - you know a few people with a complex like Alec Baldwins. Alec Baldwin says, "You ask me if I have a God complex. Let me tell you something: I am God". Click for the entire 1:30 scene, courtesy of YouTube.

For those of you who do not know her yet - consider today your lucky day!! She is Amy Tenderich and her site, Diabetes Mine, is a force to be reckoned with in the diabetes online community. What do I mean? When Amy speaks - anybody who's anybody in the diabetes online community listens.

A few months ago she posted an open letter to Steve Jobs, which was wildly discussed in the blogosphere and media. She invited gadget designers to rise to the challenge of creating sleeker, cooler, consumer-oriented medical devices for people with diabetes. Not only did she get the diabetes blogosphere stirring - but the minds of entrepreneurs storming, as well.

Amy motivated a San Francisco-based company to react in a universal remote control sort of way. Adaptive Path has designed The Charmr, a prototype of a continuous glucose monitor combined with an insulin pump, universally controlled by a device that looks to be no bigger than a USB stick! I strongly encourage everybody to checkout Amy's blog with all the details (including reader feedback) and the YouTube video on the Charmr. Bravo Amy!!

The scientific community has been in a heated debate about xenotransplants (transplanting pig islets into humans). Although the procedures are showing to be effective - is the insulin secretion entirely pig? Some experts surmise that after the transplants, diabetic patients are actually able to produce some insulin on their own, after all.

The latest press release from Tissera, Inc (an Israeli-based company) made a statement that raises my hopes. It was, "By the fourth month after transplantation, the insulin dose needed to maintain near-normal blood sugar levels decreased by more than 90% in comparison with the insulin dose needed before transplantation, meaning that endogenous insulin production was predominantly responsible for blood sugar control."

The question of the origin of endogenous insulin was addressed by measurement of blood C-peptide. C-peptide splits from insulin and indicates the level of insulin secretion from the patient. C-peptide levels were measured both at baseline and in response to a sugar load, which brings about a rise in blood C-peptide. The measured C-peptide was shown to be predominantly of pig origin. So herein lies my question: is predominantly more than 50%? A type 1 diabetic has undetectable levels of C-peptide. Period. After the xenotransplant the C-peptide level is all of a sudden detectable? Could these islet transplants assist in regenerating the diabetics' own islets?

What do you see when you picture THE CURE? The proverbial cure has always been a pill or a shot - just once. Problem solved. Well, if you look at the long list of Type 2 diabetics who have already been cured - it seems a cure will only come one way: the hard way!

Google sent me to this page posted by the Alternative Cancer Treatment Centers. The information first explains where Type 2 diabetes derives: a derangement in essential fatty acids. Specifically and statistically speaking - the fact that we consume twice as many Omega 6s as Omega 3s. The Omega 6s have become the main building blocks of the fats in our diets and therefore the fat in our bodies. This seems to be a triggering event for the rising incidences of obesity, heart disease, and Type 2 diabetes.

So now what? Okay, the page details about 44 things one must do, and continue to do for however long it takes to cure you. Don't read too much into my cynicism. I'm all about the Udo's and dosing up on the Omega 3s over 6s but when the supplement list gets longer than my Christmas List from 1988 - something's got to give! Now does anybody out there have a Type 2 Cure story to share? This is your chance - tell the world your secret to success!

ImmunoMod has received an FDA Orphan Drug Grant award to pursue human trials focused on preventing the onset of Type 1 Diabetes by protecting beta cell function in early-stage diabetic youth.

When diabetes is first diagnosed, a short window of time known as "the honeymoon stage" exists to preserve the body's ability to create insulin. During this critical stage an individual has the best chance to protect the beta cells and stop the onset of the disease. Studies have shown that regeneration of damaged cells can occur if beta cells can be preserved. The problem to date has been the inability to prolong the preservation of these beta cells.

While some treatments have decelerated beta cell destruction, their effects have been temporary, caused toxic effects and required continuous treatment. ImmunoMod appears to effectively and safely protect beta cells for prolonged periods of time. The goal is to retard or reverse the destruction of these cells during the honeymoon phase, when cells first begin to lose function, which typically lasts about six months. I wonder if it's possible to reintroduce the honeymoon stage for Type 1 diabetics who have already been diabetic for decades?

Dr. Faustman's lab is currently collecting blood samples from individuals with established Type 1 diabetes. These samples are being used to quantify the number of autoreactive T-cells and develop the adequate dosage for Phase 1 of human trials to cure Type 1 diabetes.

The research has been presented and the NIH confirmed it. By reeducating the confused T-cells and instructing them not to attack healthy islets, an apparent cure of established type 1 diabetes in non-obese diabetic mice is possible. Now, Dr. Faustman is collecting human samples to bestow the same cure for diabetes in humans.

If you wish to be a part of this revolutionary event for curing Type 1 diabetes, please contact the Clinical Coordinator or call Dr. Faustman's lab at (617) 726-4084. Each participant is asked to bring a control person along with them - an unrelated person without Type 1 diabetes or another autoimmune disease. Diabetic or not - you can be a part of history in curing Type 1 diabetes!

Last month Bev addressed a news article that found high tech diabetes management did not equate to better diabetes care. Doctors felt that electronic care is only as good as the patient willing to participate beyond office visits. However, another service is trying to evolve the preconceived notions with a more developed system - and a bigger bang for the buck. How does $14.5 billion sound?

Information technology enabled diabetes management (ITDM) was found to be beneficial in avoiding diabetic complications - MILLIONS of cases. This is an overzealous finding - considering the word prevent is permanent and should probably be replaced with delayed. Even the DCCT knew that much. However, the study was conducted over a period exclusive to the program, and not the lifespan of diabetics in the study. However patient compliance did grow from less than 50% to approximately 80%. That would evoke a few halleluiahs from doctors. Another reason in support of ITDM is the fact that an electronic diabetes registry offers Medicare and other payers the ability to save quite a bit. Over 10 years, the overall net savings is estimated to be $14.5 billion. Does that figure include COLA - cost of long-term diabetes complications adjustment? The complications that did not occur in 2008 saved Medicare and payers $1.45 billion. Score! What is the inflation adjusted cost of those delayed complications occurring in 2013?

The headcount standing at 20 million diabetics, at a savings of $1.45 billion per year - I asked for clarification on that figure. The savings is speculative because the company is anticipating saving costs on preventing diabetic complications. That's optimistic but not entirely realistic.

In light of Novo's Meet the Face of Change campaign, I figured I'd address an idea worthy of mention coming out of the Novo product pipeline. This treatment is for Type 2 diabetics but it is not insulin - it's called liraglutide. Liraglutide is a once-daily human analog of the natural hormone Glucagon-Like Peptide-1 (GLP-1). It causes neither excessive hypoglycemia nor weight gain.

Liraglutide works by stimulating the release of insulin only when glucose levels become too high. Unlike many other diabetes drugs - liraglutide also leads to weight loss instead of weight gain. Now we're getting somewhere, Novo!! Patients with Type 2 diabetes treated with liraglutide had a greater reduction in average blood sugar than those patients treated with placebo or insulin glargine (Lantus). As expected, the combination of a GLP-1 analog with a sulfonylurea caused some of the patients to experience hypoglycemia. Okay, point taken. So why impose a glucose lowering drug while mitigating the problem causing elevated sugar in the first place? One drug at a time, folks.

So this is a step in the right direction and I like where it is going. Treating Type 2 diabetes with insulin is counter-intuitive. Looking at another hormone that might interfere with the use of insulin might be the culprit. So here lies a very good idea and I like it. Gold star, Novo! Now when can we meet the face of liraglutide?

Meet the Face of Change is a photo exhibit owned by Novo Nordisk featuring YOU -- the face of change. Change for what, I asked? Well, it seems Novo would like to change your opinion of the barriers to insulin treatment for Type 2 diabetics. The common belief of insulin treatment for Type 2 diabetes is that it is the point of no return. Why? First instincts are usually correct.

Studies have shown that Type 2 diabetics injecting insulin create insulin antibodies (IAA). Type 1 diabetics have these antibodies upon diagnosis. Type 1 diabetes was also formerly referred to as insulin-dependent diabetes. Insulin antibodies (IAA) develop and attack the natural insulin produced, resulting in insulin dependence. Type 2 diabetics do not have the same level of IAA. Once they begin injecting insulin that looks like human insulin (the kind Novo makes) - you run the risk of developing IAA. The use of animal-insulins did not cause the development of IAA to the same extent. If you plan to start injecting insulin - ask your doctor if he will check you for IAA. As a Type 2 diabetic, you DO NOT have to become an insulin-dependent diabetic.

I asked Novo to explain what Meet the Face of Change is about. What are they trying to change? The response I received from Nov explains their wishes to strengthen the drive of their business, among other core values. Now I ask you - how do you drive a business that sells insulin? Sell more insulin. For the 16 million Type 2s not yet in this lineup- please consider if insulin-dependent diabetes is the face you want to meet. Don't add insulin to injury. It may not be the path of least resistance, but cut back on simple sugars, increase fiber consumption, and take a walk after dinner. Meet the face of change by putting your best foot forward, not your face on a campaign for vulture capitalism.

Lately the news has seen a lot of devastating diabetic events due to hypoglycemic unawareness. Hypoglycemic unawareness is commonly defined as an inability to recognize the symptoms (sweating, tremor, hunger, anxiety, and palpitations) of decreased blood sugar or a failure of the warning signs to occur before development of neuroglycopenia, which means a shortage of glucose in the brain. Curiously, this term was not coined for diabetes until 10 years after the introduction of genetically modified human synthetic insulin and insulin analogues.

I hate to say it but diabetes is a crapshoot. You never know what you are going to get, but you can sure try your best to keep your eye on the ball. Removing the inherent dangers of hypoglycemic unawareness would make me a happier diabetic, and improve the lives of all those I care about (diabetics like myself). The answer might lie in the only type of treatment available nowadays, insulin analogues. Diabetics who do not take any form of drug to control blood sugar do NOT have hypoglycemic unawareness.

It's called human but it is nothing like natural human insulin. It may be faster acting or longer lasting but I'm sure He didn't intend for insulin to break sound barriers or last three moons. If Big Pharmaceutical companies were asked to compare insulin analogues with natural human insulin you'd hear crickets. I promise you NO Big Pharma will fund a study that would become the antithesis of their marketing campaigns, human insulin is better. It's not better, it's just different -- totally different! Natural insulin is fat-loving. Insulin analogues are water-loving. The global command center of the body (the brain) is one big blob of fatty material. This means as your blood sugar is dropping, your brain is last fed, if it eats at all. Here in the United States we are victims of circumstance in hypoglycemic unawareness. Sorry brain, no soup for you.

Last week Amy Tenderich, creator of Diabetes Mine and co-author of Know Your Numbers, Outlive Your Diabetes, sent out an email asking us to speak out on behalf of Mr. Universe. I remembered the gist of the story when it first happened, back in April. What I didn't realize was the ensuing atrocities for Mr. Burns after the event.

Back in April, Doug Burns was maced by police during a hypoglycemic event at a movie theater. During the episode, the police assumed he was intoxicated, despite a bystander's insistence that it might be a diabetes issue. He was handcuffed, thrown into a car, and driven to a nearby ER without proper treatment for his hypoglycemia. Officers arrested him for assault and resisting arrest. Prosecutors initially insisted Burns needed to provide more medical evidence that he was a Type I diabetic suffering from insulin shock at the time. For some unknown reason -- a blood sugar of 40 isn't proof enough? The records from the event show that Doug never struck anyone, and in fact, he was the only party injured in the incident. However, the case was raised to assault and resisting arrest when one of the policemen suddenly reported an injury -- week-and-half later.

Turns out the county prosecutors have dropped misdemeanor charges against Mr. Universe. Ladies and gentleman, this is proof of how misinformed the general public is of the hurdles diabetics must overcome to continue life, uninterrupted. I'm proud to say that when issues are raised, awareness prevails. Thanks to everybody who called into the DAs office last week and thanks to Amy for calling out for the help.

Congressional investigators have been looking into very serious claims that Avandia's maker silenced medical professionals who attempted to speak out about the potential for cardiovascular problems by using the drug.

Dr. Buse, who is about to become the president of the American Diabetes Association, was an early and frequent critic of Avandia after it reached the market in 1999. In a March 2000 letter to the F.D.A., he said Avandia might raise patients' risk of heart attacks, and he criticized the company's marketing, saying it employed "blatant selective manipulation of data" to overstate the drug's benefits and understate its risks.

More recent questions about Avandia's potential risks, as outlined in a New England Journal of Medicine article last week, have prompted the Congressional hearing. The author of that article, Dr. Steven E. Nissen, a heart specialist at the Cleveland Clinic, has also been called to testify. See the full story on the upcoming congressional hearing.